Editorial
Uso de anti-VEGF (anti-vascular endothelial growth factor) en la retinopatía del prematuro
Use of anti-VEGF (anti-vascular endothelial growth factor) in Retinopathy of Prematurity (ROP)
I. González Viejo
, C. Ferrer Novella, V. Pueyo Royo
Autor para correspondencia
Servicio de Oftalmología, Hospital Universitario Miguel Servet, Zaragoza, España
Leído
2454
Vecesse ha leído el artículo
723
Total PDF
1731
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 11 | 0 | 8 | 8 |
| 2025 10 | 0 | 7 | 7 |
| 2025 9 | 0 | 8 | 8 |
| 2025 6 | 0 | 1 | 1 |
| 2025 5 | 0 | 4 | 4 |
| 2025 4 | 0 | 1 | 1 |
| 2025 3 | 0 | 2 | 2 |
| 2025 2 | 0 | 3 | 3 |
| 2025 1 | 0 | 1 | 1 |
| 2024 12 | 0 | 2 | 2 |
| 2024 11 | 0 | 1 | 1 |
| 2024 10 | 0 | 3 | 3 |
| 2024 9 | 0 | 3 | 3 |
| 2024 8 | 0 | 3 | 3 |
| 2024 7 | 0 | 1 | 1 |
| 2024 5 | 0 | 3 | 3 |
| 2024 4 | 0 | 12 | 12 |
| 2024 3 | 0 | 11 | 11 |
| 2024 2 | 0 | 2 | 2 |
| 2024 1 | 0 | 1 | 1 |
| 2023 12 | 0 | 5 | 5 |
| 2023 11 | 0 | 10 | 10 |
| 2023 10 | 0 | 8 | 8 |
| 2023 8 | 0 | 2 | 2 |
| 2023 7 | 0 | 10 | 10 |
| 2023 6 | 0 | 12 | 12 |
| 2023 5 | 0 | 1 | 1 |
| 2023 4 | 0 | 1 | 1 |
| 2023 3 | 0 | 2 | 2 |
| 2023 2 | 0 | 2 | 2 |
| 2022 1 | 0 | 2 | 2 |
| 2022 12 | 0 | 1 | 1 |
| 2022 11 | 0 | 4 | 4 |
| 2022 10 | 0 | 7 | 7 |
| 2022 9 | 0 | 3 | 3 |
| 2022 8 | 0 | 4 | 4 |
| 2022 7 | 0 | 4 | 4 |
| 2022 6 | 0 | 6 | 6 |
| 2022 5 | 0 | 3 | 3 |
| 2022 4 | 0 | 2 | 2 |
| 2022 3 | 0 | 4 | 4 |
| 2021 1 | 0 | 9 | 9 |
| 2021 12 | 0 | 2 | 2 |
| 2021 11 | 0 | 6 | 6 |
| 2021 10 | 0 | 5 | 5 |
| 2021 8 | 0 | 1 | 1 |
| 2021 6 | 0 | 3 | 3 |
| 2021 4 | 0 | 19 | 19 |
| 2021 2 | 0 | 1 | 1 |
| 2020 1 | 0 | 18 | 18 |
| 2020 12 | 2 | 12 | 14 |
| 2020 11 | 0 | 5 | 5 |
| 2020 10 | 0 | 2 | 2 |
| 2020 8 | 0 | 2 | 2 |
| 2020 7 | 1 | 2 | 3 |
| 2020 5 | 0 | 4 | 4 |
| 2020 4 | 0 | 7 | 7 |
| 2020 3 | 0 | 6 | 6 |
| 2020 2 | 0 | 7 | 7 |
| 2020 1 | 0 | 5 | 5 |
| 2019 12 | 0 | 3 | 3 |
| 2019 11 | 0 | 1 | 1 |
| 2019 10 | 0 | 7 | 7 |
| 2019 9 | 0 | 2 | 2 |
| 2019 8 | 0 | 2 | 2 |
| 2019 7 | 0 | 9 | 9 |
| 2019 6 | 0 | 9 | 9 |
| 2019 5 | 0 | 35 | 35 |
| 2019 4 | 0 | 11 | 11 |
| 2019 3 | 0 | 5 | 5 |
| 2019 2 | 1 | 3 | 4 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 0 | 6 | 6 |
| 2018 11 | 0 | 7 | 7 |
| 2018 10 | 0 | 15 | 15 |
| 2018 2 | 12 | 0 | 12 |
| 2018 1 | 3 | 1 | 4 |
| 2017 12 | 12 | 1 | 13 |
| 2017 11 | 12 | 2 | 14 |
| 2017 10 | 8 | 0 | 8 |
| 2017 9 | 13 | 11 | 24 |
| 2017 8 | 12 | 2 | 14 |
| 2017 7 | 11 | 0 | 11 |
| 2017 6 | 11 | 6 | 17 |
| 2017 5 | 10 | 1 | 11 |
| 2017 4 | 4 | 0 | 4 |
| 2017 3 | 11 | 40 | 51 |
| 2017 2 | 11 | 5 | 16 |
| 2016 1 | 8 | 0 | 8 |
| 2016 12 | 21 | 4 | 25 |
| 2016 11 | 30 | 7 | 37 |
| 2016 10 | 47 | 8 | 55 |
| 2016 9 | 25 | 11 | 36 |
| 2016 8 | 17 | 5 | 22 |
| 2016 7 | 16 | 1 | 17 |
| 2016 6 | 25 | 21 | 46 |
| 2016 5 | 26 | 10 | 36 |
| 2016 4 | 24 | 9 | 33 |
| 2016 3 | 33 | 9 | 42 |
| 2016 2 | 14 | 12 | 26 |
| 2015 1 | 18 | 9 | 27 |
| 2015 12 | 19 | 15 | 34 |
| 2015 11 | 13 | 7 | 20 |
| 2015 10 | 19 | 13 | 32 |
| 2015 9 | 14 | 4 | 18 |
| 2015 8 | 14 | 5 | 19 |
| 2015 7 | 19 | 4 | 23 |
| 2015 6 | 13 | 0 | 13 |
| 2015 5 | 23 | 6 | 29 |
| 2015 4 | 11 | 10 | 21 |
| 2015 3 | 23 | 11 | 34 |
| 2015 2 | 10 | 1 | 11 |
| 2015 1 | 21 | 3 | 24 |
| 2014 12 | 36 | 6 | 42 |
| 2014 11 | 24 | 3 | 27 |
| 2014 10 | 35 | 5 | 40 |
| 2014 9 | 37 | 3 | 40 |
| 2014 8 | 27 | 3 | 30 |
| 2014 7 | 19 | 6 | 25 |
| 2014 6 | 34 | 1 | 35 |
| 2014 5 | 23 | 5 | 28 |
| 2014 4 | 20 | 5 | 25 |
| 2014 3 | 13 | 6 | 19 |
| 2014 2 | 15 | 3 | 18 |
| 2014 1 | 14 | 2 | 16 |
| 2013 12 | 16 | 3 | 19 |
| 2013 11 | 22 | 3 | 25 |
| 2013 10 | 10 | 5 | 15 |
| 2013 9 | 12 | 3 | 15 |
| 2013 8 | 10 | 3 | 13 |
| 2013 7 | 6 | 2 | 8 |
| 2011 6 | 721 | 0 | 721 |
Mostrar todo
